$3.47
17.63%
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US15117F3029
Symbol
CLRB

Cellectar BioSciences, Inc. Stock price

$3.47
-0.15 4.14% 1M
-1.26 26.64% 6M
+0.52 17.63% YTD
-6.28 64.40% 1Y
-47.83 93.24% 3Y
-617.53 99.44% 5Y
-21,956.53 99.98% 10Y
-183,599,996.53 100.00% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.52 17.63%
ISIN
US15117F3029
Symbol
CLRB
Industry

Key metrics

Basic
Market capitalization
$14.7m
Enterprise Value
$2.2m
Net debt
positive
Cash
$12.6m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
61.5%
Return on Equity
-284.4%
ROCE
-311.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-30.1m | -
EBIT
$-30.3m | $-23.7m
Net Income
$-18.9m | $-37.7m
Free Cash Flow
$-29.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
41.0% | -
EBIT
40.9% | 54.2%
Net Income
62.3% | 15.5%
Free Cash Flow
36.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-6.0
FCF per Share
$-9.4
Short interest
2.5%
Employees
11
Rev per Employee
$0.0
Show more

Is Cellectar BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Cellectar BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Cellectar BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
35% 35%
-
- Research and Development Expense 15 15
48% 48%
-
-30 -30
41% 41%
-
- Depreciation and Amortization 0.23 0.23
21% 21%
-
EBIT (Operating Income) EBIT -30 -30
41% 41%
-
Net Profit -19 -19
62% 62%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cellectar BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectar BioSciences, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors
Neutral
Seeking Alpha
about 2 months ago
Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Officer Conference Call Participants Anne Marie Fields Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division ...
Neutral
GlobeNewsWire
about 2 months ago
Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP)
More Cellectar BioSciences, Inc. News

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Head office United States
CEO James Caruso
Employees 11
Founded 1996
Website www.cellectar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today